Literature DB >> 25724563

Liver X receptor regulates hepatic nuclear O-GlcNAc signaling and carbohydrate responsive element-binding protein activity.

Christian Bindesbøll1, Qiong Fan1, Rikke C Nørgaard1, Laura MacPherson2, Hai-Bin Ruan3, Jing Wu3, Thomas Å Pedersen4, Knut R Steffensen5, Xiaoyong Yang6, Jason Matthews7, Susanne Mandrup4, Hilde I Nebb1, Line M Grønning-Wang1.   

Abstract

Liver X receptor (LXR)α and LXRβ play key roles in hepatic de novo lipogenesis through their regulation of lipogenic genes, including sterol regulatory element-binding protein (SREBP)-1c and carbohydrate responsive element-binding protein (ChREBP). LXRs activate lipogenic gene transcription in response to feeding, which is believed to be mediated by insulin. We have previously shown that LXRs are targets for glucose-hexosamine-derived O-linked β-N-acetylglucosamine (O-GlcNAc) modification enhancing their ability to regulate SREBP-1c promoter activity in vitro. To elucidate insulin-independent effects of feeding on LXR-mediated lipogenic gene expression in vivo, we subjected control and streptozotocin-treated LXRα/β(+/+) and LXRα/β(-/-) mice to a fasting-refeeding regime. We show that under hyperglycemic and hypoinsulinemic conditions, LXRs maintain their ability to upregulate the expression of glycolytic and lipogenic enzymes, including glucokinase (GK), SREBP-1c, ChREBPα, and the newly identified shorter isoform ChREBPβ. Furthermore, glucose-dependent increases in LXR/retinoid X receptor-regulated luciferase activity driven by the ChREBPα promoter was mediated, at least in part, by O-GlcNAc transferase (OGT) signaling in Huh7 cells. Moreover, we show that LXR and OGT interact and colocalize in the nucleus and that loss of LXRs profoundly reduced nuclear O-GlcNAc signaling and ChREBPα promoter binding activity in vivo. In summary, our study provides evidence that LXRs act as nutrient and glucose metabolic sensors upstream of ChREBP by modulating GK expression, nuclear O-GlcNAc signaling, and ChREBP expression and activity.
Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  O-linked β-N-acetylglucosamine; O-linked β-N-acetylglucosamine transferase; carbohydrate responsive element-binding protein α; carbohydrate responsive element-binding protein β; chromatin immunoprecipitation; glucose; insulin; lipid metabolism

Mesh:

Substances:

Year:  2015        PMID: 25724563      PMCID: PMC4373736          DOI: 10.1194/jlr.M049130

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  59 in total

1.  Activation of LXR increases acyl-CoA synthetase activity through direct regulation of ACSL3 in human placental trophoblast cells.

Authors:  M Susanne Weedon-Fekjaer; Knut Tomas Dalen; Karianne Solaas; Anne Cathrine Staff; Asim K Duttaroy; Hilde Irene Nebb
Journal:  J Lipid Res       Date:  2010-03-10       Impact factor: 5.922

Review 2.  Genetic control of de novo lipogenesis: role in diet-induced obesity.

Authors:  Maggie S Strable; James M Ntambi
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-06       Impact factor: 8.250

Review 3.  O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation.

Authors:  David J Vocadlo
Journal:  Curr Opin Chem Biol       Date:  2012-11-10       Impact factor: 8.822

4.  Genome-wide analysis of SREBP-1 binding in mouse liver chromatin reveals a preference for promoter proximal binding to a new motif.

Authors:  Young-Kyo Seo; Hansook Kim Chong; Aniello M Infante; Seung-Soon Im; Xiaohui Xie; Timothy F Osborne
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-04       Impact factor: 11.205

5.  The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism.

Authors:  Kathryn E Wellen; Chao Lu; Anthony Mancuso; Johanna M S Lemons; Michael Ryczko; James W Dennis; Joshua D Rabinowitz; Hilary A Coller; Craig B Thompson
Journal:  Genes Dev       Date:  2010-11-24       Impact factor: 11.361

6.  De novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health.

Authors:  Leah Eissing; Thomas Scherer; Klaus Tödter; Uwe Knippschild; Jan Willem Greve; Wim A Buurman; Hans O Pinnschmidt; Sander S Rensen; Anna M Wolf; Alexander Bartelt; Joerg Heeren; Christoph Buettner; Ludger Scheja
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

7.  Nuclear receptor liver X receptor is O-GlcNAc-modified in response to glucose.

Authors:  Elin Holter Anthonisen; Lise Berven; Sverre Holm; Maria Nygård; Hilde I Nebb; Line M Grønning-Wang
Journal:  J Biol Chem       Date:  2009-11-20       Impact factor: 5.157

8.  Interrelationship between liver X receptor alpha, sterol regulatory element-binding protein-1c, peroxisome proliferator-activated receptor gamma, and small heterodimer partner in the transcriptional regulation of glucokinase gene expression in liver.

Authors:  Tae-Hyun Kim; Hail Kim; Joo-Man Park; Seung-Soon Im; Jin-Sik Bae; Mi-Young Kim; Ho-Geun Yoon; Ji-Young Cha; Kyung-Sup Kim; Yong-Ho Ahn
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

Review 9.  Cracking the O-GlcNAc code in metabolism.

Authors:  Hai-Bin Ruan; Jay Prakash Singh; Min-Dian Li; Jing Wu; Xiaoyong Yang
Journal:  Trends Endocrinol Metab       Date:  2013-05-04       Impact factor: 12.015

10.  A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism.

Authors:  Mark A Herman; Odile D Peroni; Jorge Villoria; Michael R Schön; Nada A Abumrad; Matthias Blüher; Samuel Klein; Barbara B Kahn
Journal:  Nature       Date:  2012-04-19       Impact factor: 49.962

View more
  22 in total

Review 1.  SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology.

Authors:  Hitoshi Shimano; Ryuichiro Sato
Journal:  Nat Rev Endocrinol       Date:  2017-08-29       Impact factor: 43.330

Review 2.  The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux.

Authors:  Varman T Samuel; Gerald I Shulman
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

Review 3.  Lipidomic and Membrane Mechanical Signatures in Triple-Negative Breast Cancer: Scope for Membrane-Based Theranostics.

Authors:  Ruchika Dadhich; Shobhna Kapoor
Journal:  Mol Cell Biochem       Date:  2022-05-20       Impact factor: 3.396

Review 4.  A nexus of lipid and O-Glcnac metabolism in physiology and disease.

Authors:  Amber Lockridge; John A Hanover
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-30       Impact factor: 6.055

Review 5.  Transcriptional regulation of hepatic lipogenesis.

Authors:  Yuhui Wang; Jose Viscarra; Sun-Joong Kim; Hei Sook Sul
Journal:  Nat Rev Mol Cell Biol       Date:  2015-11       Impact factor: 94.444

6.  Regulation of the urea cycle by CPS1 O-GlcNAcylation in response to dietary restriction and aging.

Authors:  Jing Wu; Jiayu Liu; Kalina Lapenta; Reina Desrouleaux; Min-Dian Li; Xiaoyong Yang
Journal:  J Mol Cell Biol       Date:  2022-07-05       Impact factor: 8.185

Review 7.  Nutrition, metabolism, and epigenetics: pathways of circadian reprogramming.

Authors:  Tomoki Sato; Paolo Sassone-Corsi
Journal:  EMBO Rep       Date:  2022-04-12       Impact factor: 9.071

Review 8.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

Review 9.  O-GlcNAcylation and the Metabolic Shift in High-Proliferating Cells: All the Evidence Suggests that Sugars Dictate the Flux of Lipid Biogenesis in Tumor Processes.

Authors:  Steffi F Baldini; Tony Lefebvre
Journal:  Front Oncol       Date:  2016-01-22       Impact factor: 6.244

Review 10.  Role of O-Linked N-Acetylglucosamine Protein Modification in Cellular (Patho)Physiology.

Authors:  John C Chatham; Jianhua Zhang; Adam R Wende
Journal:  Physiol Rev       Date:  2020-07-30       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.